Opdivo Qvantig vs Tislelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Tislelizumab
Marketed by BeOne Medicines and partners
NCT03358875 · Phase 3 · completed
The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.
Next expected readout: November 2026 · NCT06704620 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Opdivo Qvantig | Tislelizumab |
|---|---|---|
| PFS, median | —Not reported | 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT035947475 other results
|
| OS, median | —Not reported | 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT035947471 other result
|
| ORR | —Not reported | 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT035947473 other results
|
| Duration of response, median | —Not reported | 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT035947473 other results
|
PFS, median
- Opdivo Qvantig
- —Not reported
- Tislelizumab
- 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT03594747
5 other results
- 7.6 vs 5.5 NCT03594747
- 7.7 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.8 vs 5.5 NCT03594747
OS, median
- Opdivo Qvantig
- —Not reported
- Tislelizumab
- 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT03594747
1 other result
- 23.3 vs 19.4 NCT03594747
ORR
- Opdivo Qvantig
- —Not reported
- Tislelizumab
- 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 73.9% vs 47.9% NCT03594747
- 70% vs 49.6% NCT03594747
- 78.2% vs 49.6% NCT03594747
Duration of response, median
- Opdivo Qvantig
- —Not reported
- Tislelizumab
- 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 8.6 vs 4.3 NCT03594747
- 10.6 vs 4.8 NCT03594747
- 8.8 vs 4.8 NCT03594747
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Opdivo Qvantig: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Opdivo Qvantig: 0 of 4 rows · Tislelizumab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tislelizumab |
|---|---|
| Dropout rate | n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultn/a: no completion milestoneTislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —Tislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result—Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | 46.6%Tislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result46.7%Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a anaemia 94.1% alopecia 69.5% neutrophil count decreased 61.9% NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultanaemia 89.2% alopecia 65% neutrophil count decreased 65% NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tislelizumab
show 5 more results
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Esophageal Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Esophageal Squamous Cell Carcinoma pipeline
Opdivo Qvantig
Marketed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Tislelizumab
Marketed by BeOne Medicines and partners
NCT03957590 · Phase 3 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 370 participants, with progression-free survival as a clinical primary endpoint. The primary comparison was not met: median progression-free survival was 29.0 versus 28.9 months, with a hazard ratio of 0.92 (95% CI 0.68–1.25; p=0.3016), so the evidence supports a well-designed but inconclusive or negative result rather than strong evidence of benefit.
Next expected readout: March 2027 · NCT07531979 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months (missed)
Result source: NCT03957590
Results for Esophageal Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opdivo Qvantig: no structured comparison results are available for Esophageal Squamous Cell Carcinoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Opdivo Qvantig's landscape · Tislelizumab's landscape